Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vafseo (vadadustat)
Pharma
Akebia sketches out pivotal Vafseo study in nondialysis patients
Akebia plans to kick off a phase 3 trial to assess Vafseo as a potential treatment for anemia in late-stage CKD patients who aren’t on dialysis.
Fraiser Kansteiner
Mar 13, 2025 3:28pm
Akebia unveils IRA-driven high price for Vafseo
Jul 11, 2024 10:54am
Akebia's Vafseo wins FDA approval 2 years after rejection
Mar 28, 2024 9:25am
After high-profile snub, Akebia plots vadadustat resubmission
Aug 24, 2023 10:40am
Akebia finds new partner for oral anemia drug in Europe
May 25, 2023 10:56am
Akebia proposes new dosing for oral anemia drug amid FDA dispute
Apr 3, 2023 11:34am
